PL192117B1 - Kompozycja o ustalonej dawce połączonego inhibitora enzymu przekształcającego angiotensynę i antagonisty kanału wapniowego i jej zastosowanie w leczeniu chorób sercowo-naczyniowych - Google Patents
Kompozycja o ustalonej dawce połączonego inhibitora enzymu przekształcającego angiotensynę i antagonisty kanału wapniowego i jej zastosowanie w leczeniu chorób sercowo-naczyniowychInfo
- Publication number
- PL192117B1 PL192117B1 PL326246A PL32624698A PL192117B1 PL 192117 B1 PL192117 B1 PL 192117B1 PL 326246 A PL326246 A PL 326246A PL 32624698 A PL32624698 A PL 32624698A PL 192117 B1 PL192117 B1 PL 192117B1
- Authority
- PL
- Poland
- Prior art keywords
- nitrendipine
- dose
- enalapril
- composition
- calcium channel
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 15
- 239000000203 mixture Substances 0.000 title claims description 37
- 229940127291 Calcium channel antagonist Drugs 0.000 title claims description 25
- 239000000480 calcium channel blocker Substances 0.000 title claims description 7
- 208000024172 Cardiovascular disease Diseases 0.000 title description 5
- 239000003112 inhibitor Substances 0.000 title description 4
- 102000004190 Enzymes Human genes 0.000 title 1
- 108090000790 Enzymes Proteins 0.000 title 1
- 230000001131 transforming effect Effects 0.000 title 1
- 229960005425 nitrendipine Drugs 0.000 claims abstract description 76
- PVHUJELLJLJGLN-INIZCTEOSA-N (S)-nitrendipine Chemical compound CCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)[C@@H]1C1=CC=CC([N+]([O-])=O)=C1 PVHUJELLJLJGLN-INIZCTEOSA-N 0.000 claims abstract description 73
- 108010061435 Enalapril Proteins 0.000 claims abstract description 60
- 229960000873 enalapril Drugs 0.000 claims abstract description 42
- GBXSMTUPTTWBMN-XIRDDKMYSA-N enalapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)CC1=CC=CC=C1 GBXSMTUPTTWBMN-XIRDDKMYSA-N 0.000 claims abstract description 42
- 238000011282 treatment Methods 0.000 claims abstract description 24
- 239000003814 drug Substances 0.000 claims abstract description 16
- 238000004519 manufacturing process Methods 0.000 claims abstract description 4
- 210000000748 cardiovascular system Anatomy 0.000 claims abstract description 3
- 239000005541 ACE inhibitor Substances 0.000 claims description 13
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 claims description 13
- 229940000425 combination drug Drugs 0.000 claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 159000000000 sodium salts Chemical class 0.000 claims description 4
- 239000002775 capsule Substances 0.000 claims description 3
- 201000010099 disease Diseases 0.000 claims description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 3
- 101710129690 Angiotensin-converting enzyme inhibitor Proteins 0.000 claims 2
- 101710086378 Bradykinin-potentiating and C-type natriuretic peptides Proteins 0.000 claims 2
- 241000124008 Mammalia Species 0.000 claims 1
- 208000037849 arterial hypertension Diseases 0.000 claims 1
- 239000000843 powder Substances 0.000 claims 1
- 229960000309 enalapril maleate Drugs 0.000 abstract description 18
- OYFJQPXVCSSHAI-QFPUQLAESA-N enalapril maleate Chemical compound OC(=O)\C=C/C(O)=O.C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)CC1=CC=CC=C1 OYFJQPXVCSSHAI-QFPUQLAESA-N 0.000 abstract description 14
- 239000008187 granular material Substances 0.000 abstract description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract description 8
- 150000003839 salts Chemical class 0.000 abstract description 6
- 239000003795 chemical substances by application Substances 0.000 abstract description 3
- 239000000546 pharmaceutical excipient Substances 0.000 abstract description 3
- 239000000080 wetting agent Substances 0.000 abstract description 3
- 239000000314 lubricant Substances 0.000 abstract description 2
- 239000003085 diluting agent Substances 0.000 abstract 2
- 230000004523 agglutinating effect Effects 0.000 abstract 1
- 238000001035 drying Methods 0.000 abstract 1
- 229910017053 inorganic salt Inorganic materials 0.000 abstract 1
- 239000004033 plastic Substances 0.000 abstract 1
- 206010020772 Hypertension Diseases 0.000 description 27
- 230000036772 blood pressure Effects 0.000 description 20
- 229940014005 enalapril and nitrendipine Drugs 0.000 description 18
- 229940079593 drug Drugs 0.000 description 14
- 230000000694 effects Effects 0.000 description 12
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 12
- 230000003276 anti-hypertensive effect Effects 0.000 description 11
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 10
- 230000000144 pharmacologic effect Effects 0.000 description 10
- 230000004044 response Effects 0.000 description 8
- 239000004480 active ingredient Substances 0.000 description 7
- 230000035487 diastolic blood pressure Effects 0.000 description 7
- 238000004090 dissolution Methods 0.000 description 7
- 229920002261 Corn starch Polymers 0.000 description 6
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- 230000001631 hypertensive effect Effects 0.000 description 6
- 235000019359 magnesium stearate Nutrition 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 6
- FTTHROYWFRGKST-BDURURIASA-M sodium;(2s)-1-[(2s)-2-[[(2s)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]propanoyl]pyrrolidine-2-carboxylate Chemical compound [Na+].C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CCC1)C([O-])=O)CC1=CC=CC=C1 FTTHROYWFRGKST-BDURURIASA-M 0.000 description 6
- UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 description 5
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 5
- 102000004270 Peptidyl-Dipeptidase A Human genes 0.000 description 5
- 108090000882 Peptidyl-Dipeptidase A Proteins 0.000 description 5
- 230000007246 mechanism Effects 0.000 description 5
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 5
- 239000008108 microcrystalline cellulose Substances 0.000 description 5
- 229940016286 microcrystalline cellulose Drugs 0.000 description 5
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 5
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 5
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 5
- 235000017557 sodium bicarbonate Nutrition 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 description 4
- 206010027525 Microalbuminuria Diseases 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- 239000002876 beta blocker Substances 0.000 description 4
- 229940097320 beta blocking agent Drugs 0.000 description 4
- 230000000052 comparative effect Effects 0.000 description 4
- 239000008120 corn starch Substances 0.000 description 4
- 238000000354 decomposition reaction Methods 0.000 description 4
- 239000002934 diuretic Substances 0.000 description 4
- 229940030606 diuretics Drugs 0.000 description 4
- 229960001021 lactose monohydrate Drugs 0.000 description 4
- 239000000902 placebo Substances 0.000 description 4
- 229940068196 placebo Drugs 0.000 description 4
- 230000035488 systolic blood pressure Effects 0.000 description 4
- 241000282472 Canis lupus familiaris Species 0.000 description 3
- 206010019280 Heart failures Diseases 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 239000002220 antihypertensive agent Substances 0.000 description 3
- 229940127088 antihypertensive drug Drugs 0.000 description 3
- 230000004872 arterial blood pressure Effects 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 238000002651 drug therapy Methods 0.000 description 3
- 238000005469 granulation Methods 0.000 description 3
- 230000003179 granulation Effects 0.000 description 3
- 150000003222 pyridines Chemical class 0.000 description 3
- 230000002459 sustained effect Effects 0.000 description 3
- YNGDWRXWKFWCJY-UHFFFAOYSA-N 1,4-Dihydropyridine Chemical compound C1C=CNC=C1 YNGDWRXWKFWCJY-UHFFFAOYSA-N 0.000 description 2
- 206010007559 Cardiac failure congestive Diseases 0.000 description 2
- 208000007342 Diabetic Nephropathies Diseases 0.000 description 2
- 206010013710 Drug interaction Diseases 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 235000019759 Maize starch Nutrition 0.000 description 2
- -1 N - ((S) -1-ethoxycarbonyl-3-phenylpropyl) L-alanyl Chemical group 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 206010002906 aortic stenosis Diseases 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 230000002939 deleterious effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 208000033679 diabetic kidney disease Diseases 0.000 description 2
- 238000007922 dissolution test Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 238000011221 initial treatment Methods 0.000 description 2
- 238000011866 long-term treatment Methods 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 230000002085 persistent effect Effects 0.000 description 2
- FFNMBRCFFADNAO-UHFFFAOYSA-N pirenzepine hydrochloride Chemical compound [H+].[H+].[Cl-].[Cl-].C1CN(C)CCN1CC(=O)N1C2=NC=CC=C2NC(=O)C2=CC=CC=C21 FFNMBRCFFADNAO-UHFFFAOYSA-N 0.000 description 2
- 230000029865 regulation of blood pressure Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 238000013112 stability test Methods 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000011287 therapeutic dose Methods 0.000 description 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 2
- 210000000689 upper leg Anatomy 0.000 description 2
- JPXPPUOCSLMCHK-UHFFFAOYSA-N 5-methoxycarbonyl-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3-carboxylic acid Chemical class COC(=O)C1=C(C)NC(C)=C(C(O)=O)C1C1=CC=CC([N+]([O-])=O)=C1 JPXPPUOCSLMCHK-UHFFFAOYSA-N 0.000 description 1
- RZTAMFZIAATZDJ-HNNXBMFYSA-N 5-o-ethyl 3-o-methyl (4s)-4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound CCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)[C@@H]1C1=CC=CC(Cl)=C1Cl RZTAMFZIAATZDJ-HNNXBMFYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 206010060965 Arterial stenosis Diseases 0.000 description 1
- 108090000312 Calcium Channels Proteins 0.000 description 1
- 102000003922 Calcium Channels Human genes 0.000 description 1
- 206010013012 Dilatation ventricular Diseases 0.000 description 1
- 208000007530 Essential hypertension Diseases 0.000 description 1
- 206010018473 Glycosuria Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 206010049694 Left Ventricular Dysfunction Diseases 0.000 description 1
- 206010024119 Left ventricular failure Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 231100000229 OECD 452 Chronic Toxicity Study Toxicity 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000001871 Tachycardia Diseases 0.000 description 1
- 206010043118 Tardive Dyskinesia Diseases 0.000 description 1
- 229940085750 ace inhibitors and calcium channel blockers Drugs 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 description 1
- 229960000830 captopril Drugs 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- HHHKFGXWKKUNCY-FHWLQOOXSA-N cilazapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H]1C(N2[C@@H](CCCN2CCC1)C(O)=O)=O)CC1=CC=CC=C1 HHHKFGXWKKUNCY-FHWLQOOXSA-N 0.000 description 1
- 229960005025 cilazapril Drugs 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 238000011284 combination treatment Methods 0.000 description 1
- 239000013065 commercial product Substances 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000011970 concomitant therapy Methods 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000003205 diastolic effect Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 229940127292 dihydropyridine calcium channel blocker Drugs 0.000 description 1
- 239000002866 dihydropyridine calcium channel blocker Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 229960003580 felodipine Drugs 0.000 description 1
- 230000024924 glomerular filtration Effects 0.000 description 1
- 230000035780 glucosuria Effects 0.000 description 1
- 230000001435 haemodynamic effect Effects 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 229960001375 lactose Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000036723 left ventricular dilatation Effects 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical group OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 150000002688 maleic acid derivatives Chemical class 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 208000019266 moderate heart failure Diseases 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000036581 peripheral resistance Effects 0.000 description 1
- 239000000810 peripheral vasodilating agent Substances 0.000 description 1
- 229960002116 peripheral vasodilator Drugs 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 238000011458 pharmacological treatment Methods 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 229960002429 proline Drugs 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 201000001474 proteinuria Diseases 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 230000036454 renin-angiotensin system Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000002226 simultaneous effect Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000008700 sympathetic activation Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000006794 tachycardia Effects 0.000 description 1
- 230000036962 time dependent Effects 0.000 description 1
- 230000001515 vagal effect Effects 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
- A61K38/556—Angiotensin converting enzyme inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Vascular Medicine (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ES009701017A ES2125198B1 (es) | 1997-05-13 | 1997-05-13 | Asociacion a dosis fija de un inhibidor de la enzima convertidora de angiotensina y de un antagonista de los canales de calcio, procedimiento para su preparacion y su utilizacion para el tratamiento de enfermees cardiovasculares. |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| PL326246A1 PL326246A1 (en) | 1998-11-23 |
| PL192117B1 true PL192117B1 (pl) | 2006-09-29 |
Family
ID=8299270
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL326246A PL192117B1 (pl) | 1997-05-13 | 1998-05-12 | Kompozycja o ustalonej dawce połączonego inhibitora enzymu przekształcającego angiotensynę i antagonisty kanału wapniowego i jej zastosowanie w leczeniu chorób sercowo-naczyniowych |
Country Status (23)
| Country | Link |
|---|---|
| EP (1) | EP0884054B9 (xx) |
| JP (1) | JP3576806B2 (xx) |
| CN (1) | CN1146418C (xx) |
| AR (1) | AR011730A1 (xx) |
| AT (1) | ATE236653T1 (xx) |
| AU (1) | AU735404B2 (xx) |
| BR (1) | BR9805597A (xx) |
| CA (1) | CA2234899C (xx) |
| CZ (1) | CZ292616B6 (xx) |
| DE (1) | DE69813083T2 (xx) |
| DK (1) | DK0884054T3 (xx) |
| ES (2) | ES2125198B1 (xx) |
| HU (1) | HUP9801075A3 (xx) |
| IL (1) | IL124253A (xx) |
| NO (1) | NO315545B1 (xx) |
| NZ (1) | NZ330447A (xx) |
| PL (1) | PL192117B1 (xx) |
| PT (1) | PT884054E (xx) |
| RU (1) | RU2182002C2 (xx) |
| SK (1) | SK284337B6 (xx) |
| TR (1) | TR199800847A3 (xx) |
| TW (1) | TW562679B (xx) |
| ZA (1) | ZA983806B (xx) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HU226950B1 (en) * | 1999-11-03 | 2010-03-29 | Richter Gedeon Nyrt | The magnesium salt of enalapril and antihypertensive pharmaceutical composition containing it |
| AU2001246883B2 (en) * | 2000-04-11 | 2004-08-12 | Sankyo Company, Limited | Stabilized pharmaceutical compositions containing calcium channel blockers |
| KR100596257B1 (ko) * | 2001-01-26 | 2006-07-03 | 쉐링 코포레이션 | 스테롤 흡수 억제제를 포함하는 조성물, 및 페록시솜 증식인자-활성화 수용체 활성화제와 스테롤 흡수 억제제를 포함하는 조성물 및 조합물 |
| UA84694C2 (ru) * | 2002-12-16 | 2008-11-25 | Киссеи Фармасьютикал Ко., Лтд. | Капсула для лечения дизурии, содержащая гранулиновое индолиновое соединение - блокатор -адренорецепторов |
| RU2618471C2 (ru) * | 2012-12-03 | 2017-05-03 | Закрытое Акционерное Общество "Вертекс" | Пероральная фармацевтическая композиция диуретика и ингибитора АПФ в микронизированной форме, лекарственное средство и его применение |
| CN109350733A (zh) * | 2018-06-08 | 2019-02-19 | 山东理工职业学院 | 一种马来酸依那普利片剂的制备方法 |
| CN109985013B (zh) * | 2019-05-10 | 2021-08-10 | 河北君圣药业有限公司 | 一种尼群地平分散片及其制备方法 |
| CN115501224A (zh) * | 2022-10-09 | 2022-12-23 | 南昌大学第一附属医院 | 马来酸依那普利叶酸片联合通心络在制备治疗高血压合并颈动脉硬化药物的应用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3437917A1 (de) * | 1984-10-17 | 1986-04-17 | Bayer Ag, 5090 Leverkusen | Kombination von dihydropyridinen mit ace-hemmern sowie ihre verwendung in arzneimitteln |
| USH734H (en) * | 1988-03-07 | 1990-02-06 | E. R. Squibb & Sons, Inc. | Method for inhibiting onset of or treating migraine headaches employing an ACE inhibitor |
| JPH01275529A (ja) * | 1988-03-21 | 1989-11-06 | E R Squibb & Sons Inc | 晩発性運動障害の抑制治療剤 |
| CA2007525A1 (en) * | 1989-01-30 | 1990-07-30 | Zola P. Horovitz | Method for facilating dieting employing an ace inhibitor |
| US5160744A (en) * | 1991-06-27 | 1992-11-03 | Alza Corporation | Verapmil therapy |
| US5246944A (en) * | 1991-08-13 | 1993-09-21 | Merck & Co., Inc. | Quinoline angiotensin ii antagonists incorporating a substituted benzyl element |
| SI9111842A (sl) * | 1991-11-25 | 1998-04-30 | Krka | Stabilna formulacija soli enalaprila, postopek za njeno pripravo in njena uporaba |
| SI9300504A (en) * | 1993-09-28 | 1995-04-30 | Krka | Process for preparation solid dispersions and deposits of calcium antagonist dihidropyrimidine derivates and pharmaceutical compositions comprising the same |
| US5573780A (en) * | 1995-08-04 | 1996-11-12 | Apotex Usa Inc. | Stable solid formulation of enalapril salt and process for preparation thereof |
-
1997
- 1997-05-13 ES ES009701017A patent/ES2125198B1/es not_active Expired - Fee Related
-
1998
- 1998-04-28 IL IL12425398A patent/IL124253A/xx not_active IP Right Cessation
- 1998-05-05 CZ CZ19981381A patent/CZ292616B6/cs not_active IP Right Cessation
- 1998-05-06 ZA ZA983806A patent/ZA983806B/xx unknown
- 1998-05-08 NO NO19982112A patent/NO315545B1/no not_active IP Right Cessation
- 1998-05-11 SK SK616-98A patent/SK284337B6/sk not_active IP Right Cessation
- 1998-05-11 AR ARP980102163A patent/AR011730A1/es active IP Right Grant
- 1998-05-11 TW TW087107210A patent/TW562679B/zh not_active IP Right Cessation
- 1998-05-12 CN CNB981098371A patent/CN1146418C/zh not_active Expired - Lifetime
- 1998-05-12 DK DK98500119T patent/DK0884054T3/da active
- 1998-05-12 CA CA002234899A patent/CA2234899C/en not_active Expired - Lifetime
- 1998-05-12 DE DE69813083T patent/DE69813083T2/de not_active Expired - Lifetime
- 1998-05-12 PT PT98500119T patent/PT884054E/pt unknown
- 1998-05-12 ES ES98500119T patent/ES2197443T3/es not_active Expired - Lifetime
- 1998-05-12 EP EP98500119A patent/EP0884054B9/en not_active Revoked
- 1998-05-12 PL PL326246A patent/PL192117B1/pl unknown
- 1998-05-12 RU RU98109345/14A patent/RU2182002C2/ru active
- 1998-05-12 AT AT98500119T patent/ATE236653T1/de active
- 1998-05-12 HU HU9801075A patent/HUP9801075A3/hu unknown
- 1998-05-13 TR TR1998/00847A patent/TR199800847A3/tr unknown
- 1998-05-13 BR BR9805597-6A patent/BR9805597A/pt active Search and Examination
- 1998-05-13 AU AU65973/98A patent/AU735404B2/en not_active Expired
- 1998-05-13 JP JP13059098A patent/JP3576806B2/ja not_active Expired - Lifetime
- 1998-05-13 NZ NZ330447A patent/NZ330447A/xx not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR100888131B1 (ko) | 시간차 투약 원리를 이용한 심혈관계 질환 치료용 복합제제 | |
| AU2001225816B2 (en) | Therapeutic combination of amlodipine and benazepril | |
| EP2591773A2 (en) | Time-delayed sustained release pharmaceutical composition comprising dapoxetine for oral administration | |
| US6162802A (en) | Synergistic combination therapy using benazepril and amlodipine for the treatment of cardiovascular disorders and compositions therefor | |
| WO2018089804A1 (en) | Methods of treating pah with combinations of ralinepag and other agents | |
| PL206069B1 (pl) | Tabletka dwuwarstwowa zawierająca cetyryzynę i pseudoefedrynę | |
| PL192117B1 (pl) | Kompozycja o ustalonej dawce połączonego inhibitora enzymu przekształcającego angiotensynę i antagonisty kanału wapniowego i jej zastosowanie w leczeniu chorób sercowo-naczyniowych | |
| PL200858B1 (pl) | Jednostka dawkowania do podawania doustnie zawierająca mirtazapinę | |
| KR101414814B1 (ko) | 염산레르카니디핀 및 발사르탄을 포함하는 복합 제제 및 이의 제조방법 | |
| US10154963B2 (en) | Controlled-release formulations comprising Torsemide | |
| MXPA98003747A (en) | Association at a fixed dose of an inhibitor of the angiotensin converter enzyme and an antagonist of calcium channels, a procedure for its preparation and its use for the treatment of cardiovascular diseases | |
| CN101690725A (zh) | 治疗心血管疾病的药物组合物及其制备方法和用途 | |
| US20040048905A1 (en) | Therapeutic combination of amlodipine and benazepril | |
| US20080287412A1 (en) | Therapeutic combination of amlodipine and benazepril/benazeprilat | |
| SA98190540B1 (ar) | جرعة مشتركة ثابتة تحتوي على مثبط لأنزيم تحويل الأنجيوتنسين وعلى عامل مضاد لقناة الكالسيوم لعلاج الأمراض القلبية الوعائية | |
| KR20090090748A (ko) | 조합 성분을 함유한 혈관질환 예방치료제 |